Melior Discovery, Inc. is a private biopharmaceutical company based in

Exton, Pennsylvania Exton is a census-designated place (CDP) in West Whiteland Township, Chester County, Pennsylvania, United States. Its population was 5,622 at the 2020 census. The Exton Square Mall and Main Street at Exton are both located within Exton along w ...

, USA. The company specializes in

drug repositioning Drug repositioning (also called drug repurposing) involves the investigation of existing drugs for new therapeutic purposes. Repurposing achievements A number of successes have been achieved, the foremost including sildenafil (Viagra) for ere ...

and has established a proprietary

phenotypic screening In genetics, the phenotype () is the set of observable characteristics or traits of an organism. The term covers the organism's morphology or physical form and structure, its developmental processes, its biochemical and physiological proper ...

platform that it uses for this purpose. Melior also offers certain contract research organization (CRO) services comprising

animal models A model organism (often shortened to model) is a non-human species that is extensively studied to understand particular biological phenomena, with the expectation that discoveries made in the model organism will provide insight into the working ...

representing different disease conditions. The Company has issued press releases disclosing partnerships with

Pfizer Pfizer Inc. ( ) is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. The company was established in 1849 in New York by two German entrepreneurs, Charles Pfizer ...

, Merck & Co., Johnson & Johnson, and

AstraZeneca AstraZeneca plc () is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. It has a portfolio of products for major diseases in areas includi ...

, all citing the use of the company’s drug repositioning technology. Melior Discovery has also used its technology to discover its own drug candidates. In March 2009, the

Food and Drug Administration The United States Food and Drug Administration (FDA or US FDA) is a List of United States federal agencies, federal agency of the United States Department of Health and Human Services, Department of Health and Human Services. The FDA is respon ...

(FDA) approved the company’s Investigational New Drug (IND) application for a type 2 diabetes therapeutic candidate, MLR-1023. In 2013, the company reported a licensing partnership with Bukwang Pharmaceutical Company LTD and the initiation of clinical trials in March 2015. In June 2016, the company reported positive results from their Phase 2a clinical study in diabetic subjects.

History

Melior Discovery was co-founded in 2005 by Dr. Andrew Reaume (President and CEO) and Dr. Michael Saporito (Vice President of Research). Its investors include Cammeby’s Capital Group, VenturEast, Osage Ventures, Mid-Atlantic Angel Group, and BioAdvance.EDGAR Search
/ref>

References

External links

Melior Discovery WebsiteMelior Discovery- Company ProfileThe Scientist Article: "Lazarus Drugs"NGP Article: "Teaching an old drug new tricks…"HighBeam

Melior Discovery
at NGP Europe
EDGAR Search Results
{{Pharmaceutical companies of the United States Pharmaceutical companies of the United States Biotechnology companies of the United States Pharmaceutical companies established in 2005 Biotechnology companies established in 2005 Companies based in Chester County, Pennsylvania Health care companies based in Pennsylvania